Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button

Home > Press > Manhattan Scientifics Promoting a New Technology to Eliminate False Positive Cancer Analysis

Abstract:
New Technology Holds Promise for Zero-Error Cancer Pathology

Present-day "Flip of the Coin" Treatment Decisions Described in NY Times

Due to outright error and case-by-case disagreement, biopsy diagnosis often leads to unnecessary surgery

Manhattan Scientifics Promoting a New Technology to Eliminate False Positive Cancer Analysis

Albuquerque, NM | Posted on July 26th, 2010

Manhattan Scientifics, Inc. (OTCBB: MHTX) said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" (*) highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.

Earlier this year Manhattan Scientifics announced that it had acquired exclusive rights to commercialize the early cancer detection technology developed by Senior Scientific, LLC, and a team of scientists led by Edward R. Flynn, Ph.D.

The non-radiation diagnostic technology, which is in the early stages of testing, uses cancer-seeking nanotechnology. Magnetic, nano-sized cancer-targeting antibodies which bind only to cancer cells are employed, and are capable of detecting a cancerous breast tumor with only 100,000 malignant cells. The current gold-standard Mammogram requires 100 million malignant cells before a tumor can be detected. The new experimental technology is 1,000 times more sensitive and capable of detecting breast cancers 3 years earlier than with Mammograms.

In an attempt to identify an appropriate industrial partner to help move the technology from "Bench to Bedside", Manhattan Scientifics is screening the medical device and biotechnology industries, and has entered into discussions with former senior management of the FDA in an effort to accelerate the process to bring product to the market.

In addition to the www.mhtx.com website, management is pleased to announce the addition of a website dedicated exclusively to the Senior Scientific LLC technology which can be accessed at www.seniorscientific.com.

Manhattan's CEO Manny Tsoupanarias said, "The technology is designed to eliminate false positives. Thus far, the cancer tests have produced objective, not subjective, results. The system is able to selectively detect cancers during their earliest state of growth, years before current detection systems." He continued, "We have a long way to go, but every journey begins with the first steps, and we are moving forward quickly." Mr. Tsoupanarias continued, "We are cash-flow positive now and we've already demonstrated our ability to "partner" with Fortune/ 1000 companies to bring nano-medicine products to market. This story in the New York Times underscores the importance of Senior Scientifics' technology which holds the potential to alter the diagnostic approach to a variety of cancers including: Breast, Ovarian, Pancreatic, Skin, Cervical, Brain (glioblastoma), Prostate, Colon, Bladder and other forms of cancer."

Senior Scientific is a pioneering company in the emerging field of nanomedicine. The company has been supported for eight years by nine grants from the National Institutes of Health and a grant from the U.S. Department of Defense. The technology is protected by issued and pending patents.

(*) www.nytimes.com/2010/07/20/health/20cancer.html?_r=1&scp=1&sq=prone%20to%20error&st=cse

Forward looking statement: Certain statements contained in this press release are "forward looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected and are not guarantees of future performance. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Manhattan Scientifics assumes no obligation and does not intend to update these forward-looking statements.

####

About Manhattan Scientifics
Manhattan Scientifics, Inc., (OTCBB: MHTX), is a leading information age enterprise focused on the nanomedicine space. Located in New Mexico, New York and Montreal, Manhattan Scientifics’ goal is to create profit for the company’s shareholders through royalty-bearing licenses with Fortune 1000 companies by marketing products that rely on the company’s patents, know-how and intellectual property. Manhattan Scientifics owns the exclusive, perpetual U.S. license to a family of patents which will enable the manufacture and marketing of super strong, ultra light-weight “nanostructured” metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union. More information about Manhattan Scientifics can be found at www.mhtx.com and at www.seniorscientific.com

For more information, please click here

Contacts:
Manhattan Scientifics, Inc.
Marvin Maslow
Director of Investor Relations
917-923-3300


European Investor Relations:
Herbert Strauss
+43-316-296-316


U.S. & Canadian Investor Relations:
Hawk Associates
Frank Hawkins
305-451-1888

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Unraveling the crystal structure of a -70° Celsius superconductor, a world first: Significant advancement in the realization of room-temperature superconductors August 25th, 2016

Stretchy supercapacitors power wearable electronics August 25th, 2016

AIM Photonics Announces Release of Process Design Kit (PDK) for Integrated Silicon Photonics Design August 25th, 2016

Semblant to Present at China Mobile Manufacturing Forum 2016 August 25th, 2016

Possible Futures

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Nanofur for oil spill cleanup: Materials researchers learn from aquatic ferns: Hairy plant leaves are highly oil-absorbing / publication in bioinspiration & biomimetics / video on absorption capacity August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

New electrical energy storage material shows its power: Nanomaterial combines attributes of both batteries and supercapacitors August 25th, 2016

Nanomedicine

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016

Tunneling nanotubes between neurons enable the spread of Parkinson's disease via lysosomes August 24th, 2016

Announcements

Analog DNA circuit does math in a test tube: DNA computers could one day be programmed to diagnose and treat disease August 25th, 2016

Silicon nanoparticles trained to juggle light: Research findings prove the capabilities of silicon nanoparticles for flexible data processing in optical communication systems August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

New electrical energy storage material shows its power: Nanomaterial combines attributes of both batteries and supercapacitors August 25th, 2016

Patents/IP/Tech Transfer/Licensing

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016

Starpharma initiates new DEP™ drug delivery program with AstraZeneca July 27th, 2016

Integration of novel materials with silicon chips makes new 'smart' devices possible July 25th, 2016

Research team led by NUS scientists develop plastic flexible magnetic memory device: Novel technique to implant high-performance magnetic memory chip on a flexible plastic surface without compromising performance July 21st, 2016

Nanobiotechnology

Analog DNA circuit does math in a test tube: DNA computers could one day be programmed to diagnose and treat disease August 25th, 2016

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic